Search

Displaying results 3851 - 3860 of 9705 in total
  1. Drug

    MTL-CEBPA

    go.drugbank.com/drugs/DB18143
    Investigational

    MTL-CEBPA is a SMARTICLES liposomal formulation of MTL-501, a small activating RNA (saRNA) oligonucleotide.

  2. Drug

    BRG01

    go.drugbank.com/drugs/DB18173
    Investigational

    BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]

  3. Drug

    Etavopivat

    go.drugbank.com/drugs/DB18176
    Investigational

    Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.

  4. Drug

    BNT111

    go.drugbank.com/drugs/DB18177
    Investigational

    It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.

  5. Drug

    LYT-200

    go.drugbank.com/drugs/DB18179
    Investigational

    LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.

  6. Drug

    ATI-1013

    go.drugbank.com/drugs/DB18185
    Investigational

    ATI-1013 is a fully human nicotine-specific monoclonal antibody.

  7. Drug

    BMN-351

    go.drugbank.com/drugs/DB18186
    Investigational

    BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA.

  8. Drug

    EDI-200

    go.drugbank.com/drugs/DB18188
    Investigational

    EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.

  9. Drug

    AGuIX

    go.drugbank.com/drugs/DB18189
    Investigational

    AGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates. … It is under development as a radiosensitizer to be used during radiation treatment of malignant glioma.

  10. Drug

    CLBS12

    go.drugbank.com/drugs/DB18192
    Investigational

    CLBS12 is a GCSF-mobilized autologous cell therapy derived from CD34+ cells being investigated for the treatment of Buerger’s disease.